Benzinga’s Top Pre- Market Losers (AUXL, GIII, EZCH, ASFI, GERN, AMED)

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) has decreased $2.50 or 7.69% to $32.50 in the pre-market after Auxilium Pharmaceuticals announced top line results for the phase IIb clinical trial for XIAFLEX in the treatment of Peyronie's disease. The 52-week trading range for AUXL is $19.33 - $37.28.

G-III Apparel Group, Ltd. (NASDAQ: GIII) has tumbled 7.67% to $19.62 in the pre-market session. Yesterday, GIII announced that it plans to offer common stock in a public offering. Piper Jaffray & Co. is acting as the sole book-running manager. Yesterday, G-III Apparel Group closed at $21.25. So far in 2009, GIII gained over 230%.

EZchip Semiconductor Ltd. (NASDAQ: EZCH) has plunged 7.22% to $11.70. Yesterday, EZchip Semiconductor announced that it has commenced a public offering of its ordinary shares. The 52-week trading range for EZCH is $9.95 - $18.12. In the last trading session, EZCH closed at $12.61.

Asta Funding, Inc. (NASDAQ: ASFI) has plunged 4.76% to $8 in the pre-market session. The 52-week trading range for ASFI is $1.00 - $9.24. So far in the current year, Asta Funding gained over 205%. In the previous trading session, ASFI closed at $8.40.

Geron Corporation (NASDAQ: GERN) has plummeted 6.47% to $5.35 in the pre-market session. So far this year, GERN is up 22%. The 52 week trading range for GERN is $3.67 -$9.24. Yesterday, Geron Corporation closed at $5.72.

Amedisys, Inc. (NASDAQ: AMED) has decreased $1.94 or 4.13% to $45. The 52-week trading range for AMED is $25.20 - $53.30. Yesterday, AMED closed at $46.94. In the last six months, Amedisys surged over 60%.